CL2008003305A1 - Injectable composition comprising an active agent selected from a defined group; at least one bioerodible polymer, at least one non-toxic solvent and optionally one or more excipients; Preparation process; use to treat mental illness or cancer. - Google Patents

Injectable composition comprising an active agent selected from a defined group; at least one bioerodible polymer, at least one non-toxic solvent and optionally one or more excipients; Preparation process; use to treat mental illness or cancer.

Info

Publication number
CL2008003305A1
CL2008003305A1 CL2008003305A CL2008003305A CL2008003305A1 CL 2008003305 A1 CL2008003305 A1 CL 2008003305A1 CL 2008003305 A CL2008003305 A CL 2008003305A CL 2008003305 A CL2008003305 A CL 2008003305A CL 2008003305 A1 CL2008003305 A1 CL 2008003305A1
Authority
CL
Chile
Prior art keywords
preparation process
excipients
cancer
optionally
injectable composition
Prior art date
Application number
CL2008003305A
Other languages
Spanish (es)
Inventor
Jain Rajesh
Singh Sukhjeet
Kumar Devrajan Sampath
Original Assignee
M/S Panacea Biotec Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by M/S Panacea Biotec Ltd filed Critical M/S Panacea Biotec Ltd
Publication of CL2008003305A1 publication Critical patent/CL2008003305A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels

Abstract

Composición inyectable que comprende al menos un ingrediente seleccionado de antipsicóticos, inhibidores de aromatasa, bloqueante adrenérgico alfa-1, inhibidores de acetilcolinesterasa, al menos un polímero bioerosionable biocompatible y un solvente no tóxico; proceso de preparación.Injectable composition comprising at least one ingredient selected from antipsychotics, aromatase inhibitors, alpha-1 adrenergic blocker, acetylcholinesterase inhibitors, at least one biocompatible bioerodible polymer and a non-toxic solvent; Preparation process.

CL2008003305A 2007-11-06 2008-11-06 Injectable composition comprising an active agent selected from a defined group; at least one bioerodible polymer, at least one non-toxic solvent and optionally one or more excipients; Preparation process; use to treat mental illness or cancer. CL2008003305A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN2321DE2007 2007-11-06

Publications (1)

Publication Number Publication Date
CL2008003305A1 true CL2008003305A1 (en) 2009-06-05

Family

ID=40626309

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008003305A CL2008003305A1 (en) 2007-11-06 2008-11-06 Injectable composition comprising an active agent selected from a defined group; at least one bioerodible polymer, at least one non-toxic solvent and optionally one or more excipients; Preparation process; use to treat mental illness or cancer.

Country Status (3)

Country Link
AR (1) AR070033A1 (en)
CL (1) CL2008003305A1 (en)
WO (1) WO2009060473A2 (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1589901A4 (en) 2002-12-20 2006-08-09 Generipharm Inc Intracutaneous injection
US10350159B2 (en) 2010-05-31 2019-07-16 Laboratories Farmacéuticos Rovi, S.A. Paliperidone implant formulation
EP2394663B1 (en) * 2010-05-31 2021-10-13 Laboratorios Farmaceuticos Rovi, S.A. Compositions for injectable in-situ biodegradable implants
US10285936B2 (en) 2010-05-31 2019-05-14 Laboratorios Farmacéuticos Rovi, S.A. Injectable composition with aromatase inhibitor
US10335366B2 (en) 2010-05-31 2019-07-02 Laboratorios Farmacéuticos Rovi, S.A. Risperidone or paliperidone implant formulation
ES2390439B1 (en) 2012-08-03 2013-09-27 Laboratorios Farmacéuticos Rovi, S.A. INJECTABLE COMPOSITION
US10463607B2 (en) 2010-05-31 2019-11-05 Laboratorios Farmaceutics Rofi S.A. Antipsychotic Injectable Depot Composition
US10881605B2 (en) 2010-05-31 2021-01-05 Laboratorios Farmaceuticos Rovi, S.A. Methods for the preparation of injectable depot compositions
SI2394664T1 (en) * 2010-05-31 2016-10-28 Laboratorios Farmaceuticos Rovi, S.A. Antipsychotic injectable depot composition
WO2012012460A1 (en) 2010-07-19 2012-01-26 Xeris Pharmaceuticals, Inc. Stable glucagon formulations for the treatment of hypoglycemia
US9757374B2 (en) 2010-10-28 2017-09-12 Aequus Pharmaceuticals Inc. Aripiprazole compositions and methods for its transdermal delivery
WO2012058091A2 (en) * 2010-10-28 2012-05-03 Alpha To Omega Pharmaceutical Consultants, Inc. Aripiprazole compositions and methods for its transdermal delivery
PT2658525T (en) 2010-12-29 2017-11-30 Medincell Biodegradable drug delivery compositions
CN105853348B (en) 2011-03-10 2019-08-30 Xeris药物公司 Parenteral injection stablizing solution
CA2830511C (en) 2011-03-18 2021-09-14 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising aripiprazole lauroxil and sorbitan laurate
BR112014009819A2 (en) * 2011-10-24 2017-04-18 Endo Pharmaceuticals Solutions "implantable reservoir-based drug release compositions and uses thereof"
EP2770981B1 (en) 2011-10-24 2017-05-24 Braeburn Pharmaceuticals, Inc. Implantable tizanidine compositions and methods of treatment thereof
KR102007057B1 (en) 2011-10-31 2019-08-02 엑스에리스 파머수티클스, 인크. Formulations for the treatment of diabetes
US9993556B2 (en) 2012-03-19 2018-06-12 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising fatty glycerol esters
CA2867121C (en) 2012-03-19 2021-05-25 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising fatty acid esters
US9999670B2 (en) 2012-03-19 2018-06-19 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising benzyl alcohol
US9125805B2 (en) 2012-06-27 2015-09-08 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of small molecule drugs
EP3718536A1 (en) 2012-09-19 2020-10-07 Alkermes Pharma Ireland Limited Pharmaceutical compositions having improved storage stability
US9018162B2 (en) 2013-02-06 2015-04-28 Xeris Pharmaceuticals, Inc. Methods for rapidly treating severe hypoglycemia
US20160022571A1 (en) * 2013-03-14 2016-01-28 Braeburn Pharmaceuticals Bvba Sprl Implantable drug delivery compositions comprising non-polymeric sorption enhancers and methods of treatment thereof
MA39495A (en) 2014-03-20 2015-09-24 Alkermes Pharma Ireland Ltd ARIIPIPRAZOLE FORMULATIONS WITH HIGHER INJECTION RATES
EP3185932A1 (en) 2014-08-06 2017-07-05 Xeris Pharmaceuticals, Inc. Syringes, kits, and methods for intracutaneous and/or subcutaneous injection of pastes
CN104189954B (en) * 2014-09-19 2017-03-29 中国科学院长春应用化学研究所 A kind of in-situ solidifying tissue engineering bracket and preparation method thereof
US9649364B2 (en) 2015-09-25 2017-05-16 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic formulations in aprotic polar solvents
ES2836805T3 (en) * 2015-08-03 2021-06-28 Tolmar International Ltd Liquid Polymer Delivery System for Extended Drug Delivery
US11590205B2 (en) 2015-09-25 2023-02-28 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
PT3377041T (en) 2015-11-16 2023-12-15 Maria Pereira Da Cruz Alves Garcia A method for morselizing and/or targeting pharmaceutically active principles to synovial tissue
WO2018015915A1 (en) 2016-07-22 2018-01-25 Cadila Healthcare Limited A parenteral controlled release composition of an atypical antipsychotic agent
KR102033686B1 (en) * 2017-05-19 2019-10-18 보령제약 주식회사 Microneedle transdermal patch comprising donepezil
JP7299166B2 (en) 2017-06-02 2023-06-27 ゼリス ファーマシューティカルズ インコーポレイテッド Precipitation-resistant small molecule drug formulation
GB2568526A (en) * 2017-11-20 2019-05-22 Rebio Tech Oy Composition
EP3761983A1 (en) 2018-03-05 2021-01-13 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
PE20210047A1 (en) 2018-06-12 2021-01-08 Farm Rovi Lab Sa INJECTABLE COMPOSITION
AR116501A1 (en) * 2018-09-25 2021-05-12 Tolmar Int Ltd LIQUID POLYMER DELIVERY SYSTEM FOR EXTENDED DRUG ADMINISTRATION
US11911499B2 (en) * 2019-11-07 2024-02-27 Resurge Therapeutics, Inc. System and method for prostate treatment
CN113209370B (en) * 2020-01-21 2023-11-28 渼颜空间(河北)生物科技有限公司 Biodegradable injection filler, preparation method and application thereof
CA3218153A1 (en) * 2021-06-30 2023-01-05 Soumya Rahima BENHABBOUR Injectable, biodegradable and removable polymer based drug suspension for ultra-long-acting drug delivery
WO2023116517A1 (en) * 2021-12-24 2023-06-29 四川科伦药物研究院有限公司 Continuous delivery preparation capable of being stably released and preparation method therefor
US11957654B2 (en) 2022-01-29 2024-04-16 Resurge Therapeutics, Inc. Treating benign prostatic hyperplasia
US11974979B2 (en) 2022-01-29 2024-05-07 Resurge Therapeutics, Inc. Treatments for benign prostatic hyperplasia

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU739469B2 (en) * 1996-12-20 2001-10-11 Alza Corporation Gel composition and methods
US7128927B1 (en) * 1998-04-14 2006-10-31 Qlt Usa, Inc. Emulsions for in-situ delivery systems
US6143314A (en) * 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
US20030049320A1 (en) * 2000-12-18 2003-03-13 Wockhardt Limited Novel in-situ forming controlled release microcarrier delivery system
RS53890B1 (en) * 2004-11-10 2015-08-31 Tolmar Therapeutics, Inc. A stabilized polymeric delivery system
GB0517673D0 (en) * 2005-08-31 2005-10-05 Astrazeneca Ab Formulation
KR20090094811A (en) * 2006-10-05 2009-09-08 파나세아 바이오테크 리미티드 Novel injectable depot compositions and process of preparation of such compositions

Also Published As

Publication number Publication date
AR070033A1 (en) 2010-03-10
WO2009060473A2 (en) 2009-05-14
WO2009060473A3 (en) 2009-10-15

Similar Documents

Publication Publication Date Title
CL2008003305A1 (en) Injectable composition comprising an active agent selected from a defined group; at least one bioerodible polymer, at least one non-toxic solvent and optionally one or more excipients; Preparation process; use to treat mental illness or cancer.
BRPI0916235A2 (en) compound, pharmaceutical composition, use of the compound or composition, and method for treating an hcv infected patient
MX361467B (en) Isoindoline compounds for use in the treatment of cancer.
ES2526606T3 (en) Solid pharmaceutical composition comprising amlodipine and losartan
AR093386A1 (en) COMPOSITION TO TREAT DIABETES OR DIABESITY INCLUDING AN OXINTOMODULIN ANALOG AND TREATMENT METHOD
CL2007002682A1 (en) COMPOUNDS DERIVED FROM 4-METHYLPIRIDOPIRIMIDINONE; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE TO TREAT ABNORMAL CELL GROWTH, LIKE CANCER.
AR054227A1 (en) COMPOSITION OF ACTIVE PRINCIPLES
PE20121555A1 (en) COMBINATION OF A POLYPLOID INDUCING AGENT AND A Bcl-2 INHIBITOR
AR068195A1 (en) COMPOSITIONS AND METHODS FOR SEED TREATMENT
AR047936A1 (en) MANIFULATION RESISTANT TRANSDERMIC DOSAGE FORM
ECSP10010548A (en) COMPOSITIONS AND METHODS OF PREPARATION AND USE OF THE SAME
CL2009000393A1 (en) Pharmaceutical composition comprising a) an activatable pharmaceutical agent, b) a plasmonic active agent; Useful for the treatment of cell proliferation disorders.
BRPI0815057A2 (en) Compound, pharmaceutical composition, and method for treating infection.
EA033311B1 (en) Benzoxaborole derivatives as antibacterial agents
CL2007003557A1 (en) COMPOUNDS DERIVED FROM NITROGEN HETEROCICLES, INHIBITORS OF THE ACTIVITY ON B-RAF; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND FOR THE TREATMENT OF CANCER.
CL2007003356A1 (en) COMPOUNDS DERIVED FROM BENZOPIRAZOLES; PROCESS FOR THE PREPARATION OF SUCH COMPOUNDS; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS AND ANOTHER ACTIVE AGENT; AND ITS USE FOR THE TREATMENT OF ASTHMA, INFLAMMATION, AMONG OTHER DISEASES.
CL2009001298A1 (en) Compounds derived from n-cyclohexyl-2-phenoxynicotinamide; pharmaceutical composition comprising them; pharmaceutical combination comprising them; and its use to treat a disease mediated by pde4.
CL2008000202A1 (en) Compounds derived from n-aryl-acetamide, trpv1 antagonist, pharmaceutical composition that comprises them, useful in the treatment of pain.
CL2007003587A1 (en) COMPOUNDS DERIVED FROM SUBSTITUTED PYRIMIDINS; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS AND ANOTHER ACTIVE AGENT; AND ITS USE TO TREAT OR PREVENT INFECTION OF HEPATITIS C.
CL2012003266A1 (en) Tamarind seed polysaccharide for use in the treatment of microbial infections; pharmaceutical and / or antimicrobial dermocosmetic composition containing said polysaccharide; use of a tamarind seed polysaccharide; method to treat and / or prevent a patient who has a microbial infection.
ZA201203689B (en) A pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a sytoplasmic glycolysis reduction agent
MX2008015775A (en) Compounds and compositions for treatment of cancer.
CL2009000964A1 (en) Compounds derived from 1-aryl-2-imino-1,2-dihydropyridine-3-carboxamide, alpha 1d adrenergic receptor antagonist, pharmaceutical composition comprising them; and its use for the treatment or prophylaxis of diseases of the lower urinary tract.
PH12017500569A1 (en) Compositions and methods for the treatment and prophylaxis of surgical site infections
BRPI0910884A2 (en) immunogenic composition, method for treating or preventing staphylococcal infection or disease, and use of an immunogenic composition.